Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Lao

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Journal for Immunotherapy of Cancer|March 14, 2017
Erratum to: Metastatic Merkel cell carcinoma response to nivolumabFrances M Walocko, Benjamin Y Scheier, Paul W Harms, et al.
Cancer Medicine|January 10, 2014
Ipilimumab and radiation therapy for melanoma brain metastasesAnn W Silk, Michael F Bassetti, Brady T West, et al.
Journal for Immunotherapy of Cancer|November 24, 2016
Metastatic Merkel cell carcinoma response to nivolumabFrances M Walocko, Benjamin Y Scheier, Paul W Harms, et al.
Gastroenterology|October 23, 2020
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor ColitisShrinivas Bishu, Joanna Melia, William Sharfman, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2019
Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapyIrene Tsung, Russell Dolan, Christopher D Lao, et al.
Trends in Cancer|March 20, 2021
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in CancerAmy E Chang, Jonathan L Golob, Thomas M Schmidt, et al.
Melanoma Research|October 20, 2015
Implications of age and conditional survival estimates for patients with melanomaMousumi Banerjee, Christopher D Lao, Lauren M Wancata, et al.
Journal of the American Academy of Dermatology|December 19, 2012
Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III diseaseMatthew C Fox, Christopher D Lao, Jennifer L Schwartz, et al.
JAMA Oncology|July 17, 2015
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical TrialsJames Larkin, Christopher D Lao, Walter J Urba, et al.
Journal of the American Academy of Dermatology|December 19, 2012
Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV diseaseMatthew C Fox, Christopher D Lao, Jennifer L Schwartz, et al.
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Journal for Immunotherapy of Cancer|March 14, 2017
Erratum to: Metastatic Merkel cell carcinoma response to nivolumabFrances M Walocko, Benjamin Y Scheier, Paul W Harms, et al.
Cancer Medicine|January 10, 2014
Ipilimumab and radiation therapy for melanoma brain metastasesAnn W Silk, Michael F Bassetti, Brady T West, et al.
Journal for Immunotherapy of Cancer|November 24, 2016
Metastatic Merkel cell carcinoma response to nivolumabFrances M Walocko, Benjamin Y Scheier, Paul W Harms, et al.
Gastroenterology|October 23, 2020
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor ColitisShrinivas Bishu, Joanna Melia, William Sharfman, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2019
Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapyIrene Tsung, Russell Dolan, Christopher D Lao, et al.
Trends in Cancer|March 20, 2021
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in CancerAmy E Chang, Jonathan L Golob, Thomas M Schmidt, et al.
Melanoma Research|October 20, 2015
Implications of age and conditional survival estimates for patients with melanomaMousumi Banerjee, Christopher D Lao, Lauren M Wancata, et al.
Journal of the American Academy of Dermatology|December 19, 2012
Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III diseaseMatthew C Fox, Christopher D Lao, Jennifer L Schwartz, et al.
JAMA Oncology|July 17, 2015
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical TrialsJames Larkin, Christopher D Lao, Walter J Urba, et al.
Journal of the American Academy of Dermatology|December 19, 2012
Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV diseaseMatthew C Fox, Christopher D Lao, Jennifer L Schwartz, et al.
Pageof 9